GlassScriptPhysician profile
Alexis S Balstad
NPI 1871811604
$2,039.32
in general payments reported to CMS, 2019-2025
30 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $222 · 2021: $508 · 2022: $333 · 2023: $370 · 2024: $92.34 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.95 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.69 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Bayer Healthcare Pharmaceuticals INC. | $189.23 | 2020-2025 | |
| Exeltis, USA INC. | $163.00 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $140.04 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $107.86 | 2022-2025 | |
| Myovant Sciences INC. | $84.43 | 2021-2022 | |
| Baxter Healthcare | $79.93 | 2023-2025 | Tisseel, Perclot |
| Astellas Pharma US INC | $75.99 | 2019-2025 | Veozah |
| Medtronic, INC. | $69.49 | 2022 | |
| Hologic Sales and Service, LLC | $68.75 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $62.79 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $54.50 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $48.51 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.73 | 2021 | |
| Lilly USA, LLC | $28.49 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.46 | 2022 | |
| Exact Sciences Corporation | $27.63 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $24.86 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.21 | 2025 | Qelbree |
| Medicem INC. | $21.76 | 2024 | |
| Covidien LP | $20.66 | 2019 | |
| Laborie Medical Technologies Corp. | $20.07 | 2024 | |
| Pfizer INC. | $19.27 | 2023 | |
| Amag Pharmaceuticals, INC. | $18.01 | 2020 | |
| Allergan, INC. | $17.46 | 2020 | |
| Organon LLC | $17.21 | 2025 | Nexplanon |
| Evofem Biosciences, INC. | $16.53 | 2021 | |
| Abbott Laboratories | $16.18 | 2023 | Freestyle Libre 3 |
| Agile Therapeutics, INC. | $15.03 | 2021 | |
| Lupin INC. | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Balstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.